Literature DB >> 5415686

Effects of allopurinol and oxipurinol on purine synthesis in cultured human cells.

W N Kelley, J B Wyngaarden.   

Abstract

In the present study we have examined the effects of allopurinol and oxipurinol on the de novo synthesis of purines in cultured human fibroblasts. Allopurinol inhibits de novo purine synthesis in the absence of xanthine oxidase. Inhibition at lower concentrations of the drug requires the presence of hypoxanthine-guanine phosphoribosyltransferase as it does in vivo. Although this suggests that the inhibitory effect of allopurinol at least at the lower concentrations tested is a consequence of its conversion to the ribonucleotide form in human cells, the nucleotide derivative could not be demonstrated. Several possible indirect consequences of such a conversion were also sought. There was no evidence that allopurinol was further utilized in the synthesis of nucleic acids in these cultured human cells and no effect of either allopurinol or oxipurinol on the long-term survival of human cells in vitro could be demonstrated. At higher concentrations, both allopurinol and oxipurinol inhibit the early steps of de novo purine synthesis in the absence of either xanthine oxidase or hypoxanthine-guanine phosphoribosyltransferase. This indicates that at higher drug concentrations, inhibition is occurring by some mechanism other than those previously postulated.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5415686      PMCID: PMC322509          DOI: 10.1172/JCI106271

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

1.  Inhibition of human leukocyte pyrimidine deoxynucleoside synthesis by allopurinol and 6-mercaptopurine.

Authors:  R C Gallo; S Perry; T R Breitman
Journal:  Biochem Pharmacol       Date:  1968-10       Impact factor: 5.858

2.  Renal clearance of oxipurinol, the chief metabolite of allopurinol.

Authors:  G B Elion; T F Yü; A B Gutman; G H Hitchings
Journal:  Am J Med       Date:  1968-07       Impact factor: 4.965

3.  Biochemical bases of accelerated purine biosynthesis de novo in human fibroblasts lacking hypoxanthine-guanine phosphoribosyltransferase.

Authors:  F M Rosenbloom; J F Henderson; I C Caldwell; W N Kelley; J E Seegmiller
Journal:  J Biol Chem       Date:  1968-03-25       Impact factor: 5.157

4.  An enzymatic basis for variation in response to allopurinol. Hypoxanthine-guanine phosphoribosyltransferase deficiency.

Authors:  W N Kelley; F M Rosenbloom; J Miller; J E Seegmiller
Journal:  N Engl J Med       Date:  1968-02-08       Impact factor: 91.245

5.  Allopurinol in the treatment of gout.

Authors:  R W Rundles; E N Metz; H R Silberman
Journal:  Ann Intern Med       Date:  1966-02       Impact factor: 25.391

6.  Metabolic effects of allopurinol and allo-xanthine.

Authors:  R W Rundles
Journal:  Ann Rheum Dis       Date:  1966-11       Impact factor: 19.103

7.  Ribonucleosides of allopurinol and oxoallopurinol. Isolation from human urine, enzymatic synthesis, and characterization.

Authors:  T A Krenitsky; G B Elion; R A Strelitz; G H Hitchings
Journal:  J Biol Chem       Date:  1967-06-10       Impact factor: 5.157

8.  Enzymatic and metabolic studies with allopurinol.

Authors:  G B Elion
Journal:  Ann Rheum Dis       Date:  1966-11       Impact factor: 19.103

9.  The inhibition of tryptophan pyrrolase by allopurinol, an inhibitor of xanthine oxidase.

Authors:  G C Becking; W J Johnson
Journal:  Can J Biochem       Date:  1967-11

10.  Metabolic studies of allopurinol, an inhibitor of xanthine oxidase.

Authors:  G B Elion; A Kovensky; G H Hitchings
Journal:  Biochem Pharmacol       Date:  1966-07       Impact factor: 5.858

View more
  11 in total

1.  Absence of chromosome damage in human lymphocytes exposed to allopurinol and oxipurinol.

Authors:  A C Stevenson; S R Silcock; J T Scott
Journal:  Ann Rheum Dis       Date:  1976-04       Impact factor: 19.103

2.  Lesch-Nyhan syndrome: absence of the mutant enzyme in erythrocytes of a heterozygote for both normal and mutant hypoxanthine-guanine phosphoribosyl transferase.

Authors:  J A McDonald; W N Kelley
Journal:  Biochem Genet       Date:  1972-02       Impact factor: 1.890

3.  The Lesch-Nyhan syndrome. Metabolic studies during administration of adenine.

Authors:  A Demus; W Kaiser; J Schaub
Journal:  Z Kinderheilkd       Date:  1973-04-04

4.  Patterns of phosphoribosylpyrophosphate and ribose-5-phosphate concentration and generation in fibroblasts from patients with gout and purine overproduction.

Authors:  M A Becker
Journal:  J Clin Invest       Date:  1976-02       Impact factor: 14.808

5.  Mutant feedback-resistant phosphoribosylpyrophosphate synthetase associated with purine overproduction and gout. Phosphoribosylpyrophosphate and purine metabolism in cultured fibroblasts.

Authors:  E Zoref; A De Vries; O Sperling
Journal:  J Clin Invest       Date:  1975-11       Impact factor: 14.808

6.  Studies on the coordinate activity and liability of orotidylate phosphoribosyltransferase and decarboxylase in human erythrocytes, and the effects of allopurinol administration.

Authors:  R M Fox; M H Wood; W J O'Sullivan
Journal:  J Clin Invest       Date:  1971-05       Impact factor: 14.808

7.  Hereditary xanthinuria. Evidence for enhanced hypoxanthine salvage.

Authors:  F A Mateos; J G Puig; M L Jiménez; I H Fox
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

8.  [The influence of allopurinol on purine- and pyrimidinesynthesis (author's transl)].

Authors:  W Gröbner; N Zöllner
Journal:  Klin Wochenschr       Date:  1978-03-15

9.  An assessment of the possible protective effect of allopurinol in acute stroke.

Authors:  R Iansek; D Packham; B S Aspey; M J Harrison
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-05       Impact factor: 10.154

10.  Pyrazolopyrimidine metabolism in parasitic protozoa.

Authors:  B Ullman
Journal:  Pharm Res       Date:  1984-09       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.